LivaNova (LIVN) Cash from Operations (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | LivaNova | 4.03 Bn | 3.45 Bn | 243.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -81.53% |
| Dec 31, 2025 | -3.13% |
| Sep 30, 2025 | 35.18% |
| Jun 30, 2025 | 162.54% |
| Mar 31, 2025 | -69.55% |
| Dec 31, 2024 | 54.35% |
| Sep 30, 2024 | 17.62% |
| Jun 30, 2024 | 334.39% |
| Mar 31, 2024 | -81.50% |
| Dec 31, 2023 | 197.52% |
| Sep 30, 2023 | 201.11% |
| Jun 30, 2023 | -186.41% |
| Mar 31, 2023 | 10.98% |
| Dec 31, 2022 | -47.52% |
| Sep 30, 2022 | 447.93% |
| Jun 30, 2022 | -139.67% |
| Mar 31, 2022 | -22.87% |
| Dec 31, 2021 | 39.77% |
| Sep 30, 2021 | -6.55% |
| Jun 30, 2021 | 31.58% |
| Mar 31, 2021 | -47.33% |
| Dec 31, 2020 | 327.23% |
| Sep 30, 2020 | 145.52% |
| Jun 30, 2020 | 82.07% |
| Mar 31, 2020 | -3,800.10% |
| Dec 31, 2019 | 103.74% |
| Sep 30, 2019 | -294.88% |
| Jun 30, 2019 | -1,082.52% |
| Mar 31, 2019 | -90.55% |
| Dec 31, 2018 | -59.09% |
| Sep 30, 2018 | 81.44% |
| Jun 30, 2018 | 38.00% |
| Mar 31, 2018 | 15.38% |
| Dec 31, 2017 | -58.02% |
| Sep 30, 2017 | 2,656.47% |
| Jun 30, 2017 | -104.96% |
| Mar 31, 2017 | -18.62% |
| Dec 31, 2016 | 10.99% |
| Oct 18, 2015 | 87.99% |
| Jul 24, 2015 | 115.87% |